Global News

Clinverse names John Musante chief commercial officer

Monday, November 24, 2014 02:34 PM

Clinverse, a provider of automated financial management technology solutions for clinical trials, has added John Musante as chief commercial officer. Musante brings more than 25 years of experience across industry sectors including health care, technology, and life sciences.

More... »


AiCure tests artificial intelligence in opioid trial

Monday, November 24, 2014 08:00 AM

AiCure, a New York-based artificial intelligence company providing advanced facial recognition and motion-sensing technology to monitor medication ingestion, has announced the start of a major clinical trial to monitor and intervene with patients receiving medication as maintenance therapy for opioid addiction.

More... »


Global oncologists share insights into cancer immunology

Monday, November 24, 2014 08:00 AM

Cancer immunotherapy has become one of the hottest fields of clinical research in decades.

More... »

Australia, New Zealand cancel agreement for joint therapeutic regulator

Friday, November 21, 2014 11:21 AM

Peter Dutton, MP, Minister for Health for Australia, and the Jonathan Coleman, Minister of Health for New Zealand, have announced their governments’ agreement to cease efforts to establish a joint therapeutic products regulator, the Australia New Zealand Therapeutic Products Agency (ANZTPA).

More... »

OncoSec Medical, University of Washington ink research agreement

Friday, November 21, 2014 11:20 AM

OncoSec Medical, a San Diego-based company developing DNA-based intratumoral cancer immunotherapies, has entered a sponsored research agreement (SRA) with the University of Washington to evaluate the immunologic mechanisms of intratumoral DNA IL-12 electroporation.

More... »

Apellis Pharmaceuticals to acquire Potentia Pharmaceuticals

Friday, November 21, 2014 11:18 AM

Apellis Pharmaceuticals, a Crestwood, Ky.-based, clinical stage immunotherapy company, will acquire Potentia Pharmaceuticals, an early stage biotechnology company also located in Crestwood. Apellis obtained the necessary intellectual property rights to develop its complement inhibitor drug compound (APL-2) in ophthalmology and plans its first clinical trial in dry age-related macular degeneration (dry AMD).

More... »

Shire to relocate 500 jobs, U.S. headquarters, to Massachusetts

Thursday, November 20, 2014 01:43 PM

Shire plans to relocate over 500 positions to Massachusetts from its Chesterbrook, Pa., site and establish Lexington, Mass., as the company’s U.S. operational headquarters. The transition is a continuation of the company’s “One Shire” efficiency program and will streamline business globally through two principal locations—Massachusetts and Switzerland—with support from a limited number of regional and country-based offices around the world.

More... »

Study: global spending on medicines to increase 30% by 2018, to $1.3 trillion

Thursday, November 20, 2014 01:38 PM

More specialty drug innovation, greater patient access to medicines and reduced impact from patent expiries will be the primary drivers of an increase in global medicine spending of up to 30% by 2018.

More... »

Altasciences expands to U.S., launches Algorithme Pharma USA

Thursday, November 20, 2014 01:36 PM

Altasciences has opened Algorithme Pharma USA, further expanding the company’s North American footprint and ability to provide comprehensive bioequivalence and phase I/IIa clinical drug development capabilities in the U.S.

More... »

Omeros reports positive data for OMS721 for thrombotic microangiopathy

Thursday, November 20, 2014 01:29 PM

Omeros has announced positive data using OMS721, the lead human monoclonal antibody for its mannan-binding lectin-associated serine protease-2 (MASP-2) program, to inhibit thrombus formation in an ex vivo pathophysiologic system of human atypical hemolytic uremic syndrome (aHUS), a form of thrombotic microangiopathy (TMA).

More... »

`
CenterWatch Data Library
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 15

Cancer Treatment Centers of America chooses WCG as its exclusive IRB, sheds five local hospital IRBs

Five southern research groups form public-private network to help save time, money for clients with early-stage biologics

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

December

Growing adoption of feasibility review committees
Early reports cite fewer amendments, improved cycle time

AMCs vying to better compete for industry trials
Working to conquer study start-up delays, IRB review process

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

November

Private equity driving dynamic CRO growth
Enables CROs to pursue long-term strategies, while giving the space credibility

Baby boomers poised to reshape clinical trials industry
Millions of tech-savvy consumers already track their health, expect new treatments as they age

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs